{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-039431","form_type":"8-K","ticker":"XAGE","cik":"0001842939","company_name":"Longevity Health Holdings, Inc.","filed_at":"2024-04-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:20.699432+00:00","generated_at":"2026-06-04T04:55:25.828405+00:00","sec_items":["2.01","8.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Carmell completes sale of Axolotl Biologix, expects $4M annual cash burn reduction","bullets":["Sale closed March 26; consideration: 3.845M common shares, 4,243 preferred shares, cancellation of $8M notes payable.","Annualized cash burn expected to drop $4M based on AxoBio's January 2024 financials.","Total debt reduction of $15.6M ($7.6M subsidiary debt + $8M notes payable).","Tangible equity increased $7M from eliminating AxoBio's negative tangible equity.","EPS dilution reduced 29% via cancellation of 8.09M fully diluted shares; 19.25M shares outstanding post-closing."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-039431","json":"https://secwatch.observer/filing/0000950170-24-039431.json","markdown":"https://secwatch.observer/filing/0000950170-24-039431.md","text":"https://secwatch.observer/filing/0000950170-24-039431.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1842939/000095017024039431/0000950170-24-039431-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1842939/000095017024039431/ctcx-20240326.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T04:55:25.828405+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"9b80d66f050cfe3ee113b13e6b192a038b9f4a88","claim":"Longevity Health Holdings, Inc. completed a disposition involving Burns Ventures, LLC, H. Rodney Burns, AXO XP, LLC, Protein Genomics, LLC (collectively, the Buyers) for 3,845,337 shares of common stock, 4,243 shares of Series A Convertible Voting Preferred Stock, and cancellation of $8 million principal amount of notes payable (closed 2024-03-26).","evidence_excerpt":"LLC, a Delaware corporation (“PGEN” and together with BVLLC, Burns, and AXPLLC, collectively, the “Buyers” and each, a “Buyer”). The consideration for the Sale consisted of (i) 3,845,337 shares of the Company’s common stock, $0.0001 par value per share, and 4,243 shares of the Company’s Series A Convertible Voting Preferred Stock, $0.0001 par value per share,","evidence_source":"SEC 8-K Item 2.01/5.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1842939/000095017024039431/0000950170-24-039431-index.htm","confidence":0.9,"family_label":"M&A Transactions","details":[{"label":"Action","value":"disposition"},{"label":"Counterparty","value":"Burns Ventures, LLC, H. Rodney Burns, AXO XP, LLC, Protein Genomics, LLC (collectively, the Buyers)"},{"label":"Consideration","value":"3,845,337 shares of common stock, 4,243 shares of Series A Convertible Voting Preferred Stock, and cancellation of $8 million principal amount of notes payable"},{"label":"Closing","value":"2024-03-26"}],"fact_type":"ma_transaction"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}